Nu Skin’s $5.21 distressed valuation embeds a failing MLM, but Prysm iO and India could create exceptional upside if management can stabilize its shrinking sales-force network.
Overview
Nu Skin Enterprises (NUS) is a global direct-selling company operating in approximately 50 markets, with 74% of revenue generated internationally and therefore meaningful foreign-exchange sensitivity. Its dual-engine portfolio spans personalized anti-aging beauty, Pharmanex wellness supplements, and the Rhyz manufacturing and innovation ecosystem. The company’s high-touch distributor model and science-led products provide differentiation, but affiliate switching costs are minimal and the network is shrinking. **Q1 2026 revenue declined 12.0% year over year to $320.6 million**, slightly below the $329.7 million consensus, while adjusted EPS was $0.14 versus $0.15 expected; GAAP diluted EPS was $0.04, although the prior-year comparison included a $176.2 million Mavely-sale gain. Management maintained 2026 revenue guidance of $1.35-$1.50 billion and adjusted EPS guidance of $0.80-$1.20. The investment case depends on Prysm iO stabilizing the sales force, converting transactional demand into subscriptions, and supporting a late-2026 India launch. At $5.21, NUS trades at 5.2x forward earnings, 4.81x trailing GAAP P/E, and 0.18x sales versus a 21.5x ten-year average P/E and 12.8x consumer-staples peer multiple. The valuation offers substantial upside only if the turnaround becomes measurable; otherwise, regulatory, covenant, and distributor attrition risks remain severe.